June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Abner Antonio Murray: Helena Yu Presented Promising Data for Zipalertinib in Previously Treated EGFR ex20ins NSCLC at ASCO25
Jun 3, 2025, 04:59

Abner Antonio Murray: Helena Yu Presented Promising Data for Zipalertinib in Previously Treated EGFR ex20ins NSCLC at ASCO25

Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post on X:

“At ASCO25, Dr. Helena Yu presented promising data for zipalertinib in previously treated EGFR ex20ins NSCLC
In this phase 1/2 study, zipalertinib showed:
  • ORR 35% (95% CI: 28–43%)
  • Clinical activity post-platinum ± amivantamab
  • ORR 24% even in the post-amivantamab group
  • CNS activity (ORR 31% in pts w/ brain mets)
  • Durable responses: median DOR 8.8 mo
  • Manageable safety, consistent with prior data
A potential option for a population with high unmet need. RESILIENT3, a phase 3 1L trial, is ongoing.”

Abner Antonio Murray: Helena Yu Presented Promising Data for Zipalertinib in Previously Treated EGFR ex20ins NSCLC at ASCO25

More posts featuring Abner Antonio Murray.